Nguyen Huu-Thinh, Luong Bac An, Tran Duc-Huy, Nguyen Trong-Hieu, Ngo Quoc Dat, Le Linh Gia Hoang, Ho Quoc Chuong, Nguyen Hue-Hanh Thi, Nguyen Cao Minh, Tran Vu Uyen, Pham Truong Vinh Ngoc, Le Minh Triet, Le Ngoc An Trinh, Le Trung Kien, Nguyen Thanh Luan, Pham Hong-Anh Thi, Le Hong Thuy, Duong Hong Diep Thi, Hoang Anh Vu, Nguyen Hoang Bac, Truong Dinh Kiet, Phan Minh-Duy, Nguyen Hoai-Nghia, Do Thanh-Thuy Thi, Giang Hoa, Tran Le Son, Tran Diep Tuan
University Medical Center, Ho Chi Minh City, Vietnam.
University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam.
Cancer Invest. 2022 Apr;40(4):354-365. doi: 10.1080/07357907.2021.2017951. Epub 2021 Dec 22.
Identification of tumor-derived mutation (TDM) in liquid biopsies (LB), especially in early-stage patients, faces several challenges, including low variant-allele frequencies, interference by white blood cell (WBC)-derived mutations (WDM), benign somatic mutations and tumor heterogeneity. Here, we addressed the above-mentioned challenges in a cohort of 50 nonmetastatic colorectal cancer patients, via a workflow involving parallel sequencing of paired WBC- and tumor-gDNA. After excluding potential false positive mutations, we detected at least one TDM in LB of 56% (28/50) of patients, with the majority showing low-patient coverage, except for one TDM mapped to that recurred in 30% (15/30) of patients.
在液体活检(LB)中识别肿瘤衍生突变(TDM),尤其是在早期患者中,面临着诸多挑战,包括低变异等位基因频率、白细胞(WBC)衍生突变(WDM)的干扰、良性体细胞突变以及肿瘤异质性。在此,我们通过一个涉及对配对的WBC和肿瘤基因组DNA(gDNA)进行平行测序的工作流程,在一组50例非转移性结直肠癌患者中应对了上述挑战。在排除潜在的假阳性突变后,我们在56%(28/50)的患者的液体活检中检测到至少一个TDM,除了一个映射到 的TDM在30%(15/30)的患者中复发外,大多数TDM显示出低患者覆盖率。